← All trials
NCT04333355
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Dec 20, 2020
- Completion date
- Apr 30, 2021
- First posted
- Apr 3, 2020
- Last posted
- Apr 3, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital San Jose Tec de MonterreyLead sponsor
- Hospital San JoséOverall official - principal investigator
- Hospital San Jose Tec de MonterreyReponsible party - principal investigator
- Tecnologico de MonterreyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.